Philadelphia chromosome-positive acute lymphoblastic leukemia

Yuichi Kodama; Hiroyuki Shimada

doi:10.1007/978-981-15-0548-5_10

Philadelphia chromosome-positive acute lymphoblastic leukemia

Yuichi Kodama, Hiroyuki Shimada

Department of Pediatrics

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

In the treatment of childhood Ph+ALL, TKI-combined chemotherapy has become the standard option, and HSCT in first remission is no longer an absolute indication. However, pediatric Ph+ALL is still a refractory leukemia, and 5-year EFS in children without HSCT in first remission was only 55-60% because of treatment-related death and post-chemotherapy relapse. Further improvement in clinical outcomes may require intensified targeted therapy in combination with low-intensity chemotherapy and/or immune antibody therapy with reduced toxicity. Continuing to address these challenges in prospective clinical studies will change childhood Ph+ALL from refractory leukemia to more manageable leukemia in the future.

Original language	English
Title of host publication	Pediatric Acute Lymphoblastic Leukemia
Publisher	Springer Singapore
Pages	93-99
Number of pages	7
ISBN (Electronic)	9789811505485
ISBN (Print)	9789811505478
DOIs	https://doi.org/10.1007/978-981-15-0548-5_10
Publication status	Published - 2019 Jan 1

Keywords

Bcr-abl1
Dasatinib
Philadelphia chromosome
Ponatinib
Tyrosine kinase inhibitor imatinib

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-981-15-0548-5_10

Cite this

@inbook{d1e34efa111243b28b0e1df8b7b50056,

title = "Philadelphia chromosome-positive acute lymphoblastic leukemia",

abstract = "In the treatment of childhood Ph+ALL, TKI-combined chemotherapy has become the standard option, and HSCT in first remission is no longer an absolute indication. However, pediatric Ph+ALL is still a refractory leukemia, and 5-year EFS in children without HSCT in first remission was only 55-60% because of treatment-related death and post-chemotherapy relapse. Further improvement in clinical outcomes may require intensified targeted therapy in combination with low-intensity chemotherapy and/or immune antibody therapy with reduced toxicity. Continuing to address these challenges in prospective clinical studies will change childhood Ph+ALL from refractory leukemia to more manageable leukemia in the future.",

keywords = "Bcr-abl1, Dasatinib, Philadelphia chromosome, Ponatinib, Tyrosine kinase inhibitor imatinib",

author = "Yuichi Kodama and Hiroyuki Shimada",

note = "Publisher Copyright: {\textcopyright} Springer Nature Singapore Pte Ltd. 2020.",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/978-981-15-0548-5_10",

language = "English",

isbn = "9789811505478",

pages = "93--99",

booktitle = "Pediatric Acute Lymphoblastic Leukemia",

publisher = "Springer Singapore",

}

TY - CHAP

T1 - Philadelphia chromosome-positive acute lymphoblastic leukemia

AU - Kodama, Yuichi

AU - Shimada, Hiroyuki

N1 - Publisher Copyright: © Springer Nature Singapore Pte Ltd. 2020.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the treatment of childhood Ph+ALL, TKI-combined chemotherapy has become the standard option, and HSCT in first remission is no longer an absolute indication. However, pediatric Ph+ALL is still a refractory leukemia, and 5-year EFS in children without HSCT in first remission was only 55-60% because of treatment-related death and post-chemotherapy relapse. Further improvement in clinical outcomes may require intensified targeted therapy in combination with low-intensity chemotherapy and/or immune antibody therapy with reduced toxicity. Continuing to address these challenges in prospective clinical studies will change childhood Ph+ALL from refractory leukemia to more manageable leukemia in the future.

AB - In the treatment of childhood Ph+ALL, TKI-combined chemotherapy has become the standard option, and HSCT in first remission is no longer an absolute indication. However, pediatric Ph+ALL is still a refractory leukemia, and 5-year EFS in children without HSCT in first remission was only 55-60% because of treatment-related death and post-chemotherapy relapse. Further improvement in clinical outcomes may require intensified targeted therapy in combination with low-intensity chemotherapy and/or immune antibody therapy with reduced toxicity. Continuing to address these challenges in prospective clinical studies will change childhood Ph+ALL from refractory leukemia to more manageable leukemia in the future.

KW - Bcr-abl1

KW - Dasatinib

KW - Philadelphia chromosome

KW - Ponatinib

KW - Tyrosine kinase inhibitor imatinib

UR - http://www.scopus.com/inward/record.url?scp=85085435314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085435314&partnerID=8YFLogxK

U2 - 10.1007/978-981-15-0548-5_10

DO - 10.1007/978-981-15-0548-5_10

M3 - Chapter

AN - SCOPUS:85085435314

SN - 9789811505478

SP - 93

EP - 99

BT - Pediatric Acute Lymphoblastic Leukemia

PB - Springer Singapore

ER -

Philadelphia chromosome-positive acute lymphoblastic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this